We are monitoring the impact of COVID-19 on Ulcerative Colitis Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 6217
Share on
Share on

Global Ulcerative Colitis Market Analysis - By Product (Monoclonal Antibodies, Biosimilars, Pharmaceuticals), By Type (Proctosigmoiditis, Ulcerative Proctitis, Pancolitis and Left-sided Colitis), By Role of Administration (Oral and Injectable), By Region - Industry Size, Share, Trends, Forecast and Growth | 2019 - 2024

Pulished: February, 2020
ID: 6217
Pages: 175

Ulcerative Colitis Market Size & Growth (2019 - 2024)

The Global Ulcerative Colitis Market was valued at USD 5.44 billion in 2019 and is projected to grow at a CAGR of 6.7%, to reach USD 7.52 billion by 2024 during the forecast period 2019 - 2024. 

Ulcerative colitis is an inflammatory bowel disease that can cause ulcers in larger intestine, irritation, inflammation. The major cause for the disease is a dysfunctional immune system resulting in failure of white blood cells, due to ulcerative colitis the white blood cells start attacking the lining of the colon leading to severe inflammation and ulcers. Ulcerative colitis does not have a complete cure but the disease can be controlled by taking proper treatments at regular intervals.

The major factor that is fueling the growth of the global ulcerative colitis market is the increasing incidence of ulcerative colitis due to the increasing population across the world. Factors such as commercialization and influx of investments in healthcare are leading to the development of novel treatment procedures which are fueling the growth of the ulcerative colitis market. Also, the availability of advanced treatments for ulcerative colitis owing to technological advancements and increasing patient pool in need of treatment are key catalyzing factors that are responsible for the growth of the ulcerative colitis market. Other responsible factors for the growth of the market are increasing demand for symptomatic therapeutics, the influx of enhancing drugs into the market, increasing adoption of steroids and biologics to treat ulcerative colitis.

The major challenge which is restricting the growth of the ulcerative colitis market is the stringent approval process of biosimilars. Unfavorable rules and policies and varying conditions in different countries are also limiting the growth of the ulcerative colitis market. Patent expiration of blockbuster drugs is expected to slow down the growth pace of the ulcerative colitis market during the forecast period.

The ulcerative colitis market is growing rapidly and is expected to offer lucrative market opportunities owing to factors such as increasing demand for treatment of ulcerative colitis, lack of medication, personalized therapy and curative therapy for ulcerative colitis. Increasing initiatives on research and developments by public and private organizations in health care are expected to boost the opportunities for stakeholders operating in the ulcerative colitis market. 

Recent developments:

  • Based on research and studies conducted in 2019 it is evident that the mitochondrial genes and function are reduced in ulcerative colitis patients and the activity of chain which transports the electrons is compromised.
  • In June 2019, Abbvie Company has completed the acquisition of Allergan to expand its product portfolio in order to offer extensively advanced treatments for patients. Allergen has developed a monoclonal antibody called brazikumab and it is implemented in the treatment of ulcerative colitis and Crohn's disease. Abbvie has launched risankizumab under skirizi brand which is in its final stage of clinical trials for the treatment of ulcerative colitis and crohn’s disease.
  • Takeda Pharmaceutical has developed a maintenance therapy for the patients affected with moderate to severe ulcerative colitis called subcutaneous ENTYVIO. The company has submitted for a biologics license application to U.S food and drug administration for which they have received the response letter from the FDA in December 2019, the company is focusing on the product getting approved by FDA. Earlier in 2018, the company has launched Entyvio for which it has received approval FDA in 2018.

Key happenings in this market in the recent past:

In May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that Takeda had reached an agreement on the terms of a proposed offer to acquire all of Shire's outstanding shares and future common shares.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 – 2024

Segments Analysed

By Product, Type, Route of Administration and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Analysed

Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche, Shire Pharmaceuticals

 

This research report on the Global Ulcerative Colitis Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.

Ulcerative Colitis Market Analysis - By Product

On the basis of product, Biosimilars hold the largest market share due to their high production in the last decade due to the patent expiration of branded drugs. The monoclonal antibodies segment is the fastest-growing segment due to its effectiveness in curing the disease.

Ulcerative Colitis Market Analysis - By Type

  • Proctosigmoiditis
  • Ulcerative Proctitis
  • Pancolitis
  • Left-sided Colitis

On the basis of type, the Proctosigmoiditis segment is the most common type of ulcerative colitis and hence it holds the major market share.

Ulcerative Colitis Market Analysis - By Route of Administration

  • Oral
  • Injectable

Regional Analysis

North America is leading the global ulcerative colitis market and this region hosts a huge number of research activities in drug development and also has a large number of pharmaceutical companies.

Asia-Pacific is anticipated to be the quickest growing market. This is attributed due to the developing healthcare sector in existing countries. In countries like India, government intervention and expansion of major pharmaceutical companies are the factors that drive this region.

Top companies leading the Global Ulcerative Colitis Market profiled in this report are:

  1. Abbott Laboratories
  2. GlaxoSmithKline
  3. Pfizer
  4. Takeda Pharmaceuticals
  5. AbbVie
  6. Johnson and Johnson
  7. Merck
  8. Sanofi
  9. F. Hoffmann-La Roche
  10. Shire Pharmaceuticals

The ulcerative colitis market is comprised of several key companies, such as AbbVie Inc., Merck, Johnson and Johnson, and others. These companies have implemented specific strategic plans, such as mergers, new product launches, acquisitions, and partnerships, to strengthen their market position.

1. Introduction        

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                                

                3.2 Key Inferences

                3.3 Epidemology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Product                                        

                                5.1.1 Introduction                           

                                5.1.2 Monoclonal Antibodies                     

       5.1.2.1 Humira  

       5.1.2.2 Simponi                

       5.1.2.3 Remicade             

                                                5.1.2.4 Entyvio  

                                5.1.3 Biosimilars                               

                                5.1.4 Pharmaceuticals                   

       5.1.4.1 Mesalamine        

                       5.1.4.1.1 Asacol HD

                       5.1.4.1.2 Pentasa

                       5.1.4.1.3 Lialda

                       5.1.4.1.4 sfRowasa

       5.1.4.2 Balsazide              

                       5.1.4.2.1 Colazal

                       5.1.4.2.2 Giazo

       5.1.4.3 Budesonide        

                                5.1.5  Y-o-Y Growth Analysis, By Product                              

                                5.1.6  Market Attractiveness Analysis, By Product                            

                                5.1.7  Market Share Analysis, By Product                              

                5.2 Type     

                                5.2.1 Introduction                           

                                5.2.2 Proctosigmoiditis                  

                                5.2.3 Ulcerative Proctitis                              

                                5.2.4 Pancolitis                 

                                5.2.5 Left-sided Colitis                   

                                5.2.5 Y-o-Y Growth Analysis, By Type                     

                                5.2.6 Market Attractiveness Analysis, By Type                   

                                5.2.7 Market Share Analysis, By Type                     

                5.3 Route of Administration                                       

                                5.3.1 Introduction                           

                                5.3.2 Oral                            

                                5.3.3 Injectable                

                                5.3.4 Y-o-Y Growth Analysis, By Route of Administration                               

                                5.3.5  Market Attractiveness Analysis, By Route of Administration                            

                                5.3.6  Market Share Analysis, By Route of Administration                             

6. Geographical Analysis                     

                6.1 Introduction      

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

       6.1.3.1 By Geographical Area     

       6.1.3.2 By Product           

       6.1.3.3 By Type 

       6.1.3.4 By Route of Administration          

                                6.1.4  Market Attractiveness Analysis                     

       6.1.4.1 By Geographical Area     

       6.1.4.2 By Product           

       6.1.4.3 By Type 

       6.1.4.4 By Route of Administration          

                                6.1.5  Market Share Analysis                      

       6.1.5.1 By Geographical Area     

       6.1.5.2 By Product           

       6.1.5.3 By Type 

       6.1.5.4 By Route of Administration          

                6.2 North America

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.3 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                            

                                6.2.6 France                       

                6.4 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                         

                                6.3.5 Australia                   

                                6.3.6 South Korea                           

                6.5 Latin America    

                                6.4.1 Introduction                           

                                6.4.2 Brazil                          

                                6.4.3 Argentina                

                                6.4.4 Mexico                     

                                6.4.5 Rest of Latin America                          

                6.6 Middle East & Africa      

                                6.5.1 Introduction                           

                                6.5.2 Middle-East                            

                                6.5.3 Africa                         

7. Strategic Analysis              

                7.1 PESTLE analysis

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis     

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8. Market Leaders' Analysis               

                8.1 Abbott Laboratories      

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 GlaxoSmithKline                                       

                8.3 Pfizer   

                8.4 Takeda Pharmaceuticals                                       

                8.5 AbbVie

                8.6 Johnson and Johnson   

                8.7 Merck  

                8.8 Sanofi  

                8.9 F. Hoffmann-La Roche  

                8.10 Shire Pharmaceuticals

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                                

                b) List of Figures     

  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis By Route Of Administraton  along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Ulcerative Colitis Market By Region, From 2019-2024( USD Billion )
  2. Global Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  3. Global Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  4. Global Biosimilars Market By Region, From 2019-2024( USD Billion )
  5. Global Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  6. Global Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  7. Global Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  8. Global Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  9. Global Pancolitis Market By Region, From 2019-2024( USD Billion )
  10. Global Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  11. Global Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  12. Global Oral Market By Region, From 2019-2024( USD Billion )
  13. Global Injectable Market By Region, From 2019-2024( USD Billion )
  14. North America Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  15. North America Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  16. North America Biosimilars Market By Region, From 2019-2024( USD Billion )
  17. North America Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  18. North America Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  19. North America Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  20. North America Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  21. North America Pancolitis Market By Region, From 2019-2024( USD Billion )
  22. North America Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  23. North America Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  24. North America Oral Market By Region, From 2019-2024( USD Billion )
  25. North America Injectable Market By Region, From 2019-2024( USD Billion )
  26. United States Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  27. United States Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  28. United States Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  29. Canada Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  30. Canada Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  31. Canada Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  32. Europe Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  33. Europe Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  34. Europe Biosimilars Market By Region, From 2019-2024( USD Billion )
  35. Europe Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  36. Europe Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  37. Europe Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  38. Europe Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  39. Europe Pancolitis Market By Region, From 2019-2024( USD Billion )
  40. Europe Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  41. Europe Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  42. Europe Oral Market By Region, From 2019-2024( USD Billion )
  43. Europe Injectable Market By Region, From 2019-2024( USD Billion )
  44. U.K. Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  45. U.K. Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  46. U.K. Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  47. Germany Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  48. Germany Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  49. Germany Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  50. France Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  51. France Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  52. France Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  53. Italy Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  54. Italy Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  55. Italy Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  56. Spain Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  57. Spain Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  58. Spain Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  59. Asia Pacific Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  60. Asia Pacific Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  61. Asia Pacific Biosimilars Market By Region, From 2019-2024( USD Billion )
  62. Asia Pacific Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  63. Asia Pacific Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  64. Asia Pacific Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  65. Asia Pacific Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  66. Asia Pacific Pancolitis Market By Region, From 2019-2024( USD Billion )
  67. Asia Pacific Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  68. Asia Pacific Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  69. Asia Pacific Oral Market By Region, From 2019-2024( USD Billion )
  70. Asia Pacific Injectable Market By Region, From 2019-2024( USD Billion )
  71. Japan Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  72. Japan Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  73. Japan Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  74. China Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  75. China Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  76. China Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  77. India Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  78. India Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  79. India Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  80. Australia Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  81. Australia Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  82. Australia Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  83. South Korea Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  84. South Korea Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  85. South Korea Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  86. Latin America Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  87. Latin America Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  88. Latin America Biosimilars Market By Region, From 2019-2024( USD Billion )
  89. Latin America Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  90. Latin America Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  91. Latin America Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  92. Latin America Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  93. Latin America Pancolitis Market By Region, From 2019-2024( USD Billion )
  94. Latin America Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  95. Latin America Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  96. Latin America Oral Market By Region, From 2019-2024( USD Billion )
  97. Latin America Injectable Market By Region, From 2019-2024( USD Billion )
  98. Brazil Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  99. Brazil Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  100. Brazil Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  101. Argentina Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  102. Argentina Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  103. Argentina Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  104. Mexico Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  105. Mexico Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  106. Mexico Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  107. Rest of Latin America Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  108. Rest of Latin America Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  109. Rest of Latin America Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  110. Middle East and Africa Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  111. Middle East and Africa Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  112. Middle East and Africa Biosimilars Market By Region, From 2019-2024( USD Billion )
  113. Middle East and Africa Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  114. Middle East and Africa Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  115. Middle East and Africa Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  116. Middle East and Africa Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  117. Middle East and Africa Pancolitis Market By Region, From 2019-2024( USD Billion )
  118. Middle East and Africa Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  119. Middle East and Africa Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  120. Middle East and Africa Oral Market By Region, From 2019-2024( USD Billion )
  121. Middle East and Africa Injectable Market By Region, From 2019-2024( USD Billion )
  122. Middle East Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  123. Middle East Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  124. Middle East Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  125. Africa Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  126. Africa Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  127. Africa Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample